FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality^® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.

Full story.

AAPM Member Dr. Barreveld Co-Authors Opioid Article for New England Journal of Medicine

Published On:

How Psychologists Can Help Treat Chronic Pain

Published On:

Largescale Real-World Migraine Study Solidifies Efficacy and Safety of Theranica’s Nerivio® Device

Published On:

AAPM is dedicated to advancing multidisciplinary pain care, education, advocacy, and research to improve the quality of life for our members and those they treat.

AAPM

Resources

Contact

10440 Little Patuxent Pkwy,
Ste. 300
Columbia, MD 21044

P: (443) 399-1502

Join Now

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

Related Posts

AAPM Member Dr. Barreveld Co-Authors Opioid Article for New England Journal of Medicine

How Psychologists Can Help Treat Chronic Pain

Largescale Real-World Migraine Study Solidifies Efficacy and Safety of Theranica’s Nerivio® Device

AAPM

Resources

Contact